Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2012
11/22/2012WO2012157647A1 Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
11/22/2012WO2012157589A1 Cell adhesion inhibitor, cell proliferation inhibitor, and method and kit for testing cancer
11/22/2012WO2012157237A1 Osteogenesis promoter
11/22/2012WO2012156733A1 Detection and depletion of hcmv infected cells
11/22/2012WO2012156437A1 Method for egfr directed combination treatment of cancer
11/22/2012WO2012156275A1 Compositions containing resveratrol and essential oil of cloves for the treatment of itching
11/22/2012WO2012065057A3 Phosphatidylinositol 3-kinase inhibitors and methods of their use
11/22/2012US20120296084 Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation
11/22/2012US20120296081 Carrageenan Based Antimicrobial Compositions
11/22/2012US20120295912 Piperazinylpiperidine derivatives as chemokine receptor antagonists
11/22/2012US20120295856 Fredericamycin derivatives
11/22/2012US20120295836 GLP-I Agonist And Cardiovascular Complications
11/22/2012US20120294901 Novel cochleate formulations
11/22/2012US20120291875 Citrate-Based Dialysate Chemical Formulations
11/22/2012CA2836568A1 Immunity induction agent
11/22/2012CA2836565A1 Diagnosis of respiratory tract infectious diseases using urine specimens
11/22/2012CA2836562A1 Diagnosis of respiratory tract infectious disease using blood specimens
11/21/2012EP2524693A1 Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
11/21/2012EP2523692A1 Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof
11/21/2012EP2523670A1 Method for producing reservoir layer for hoof treatment and reservoir layer
11/21/2012EP2523668A1 Treatment of multiple sclerosis
11/21/2012EP2260833B1 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
11/21/2012CN102792160A Methods and compositions for treating cancer
11/21/2012CN102784396A Use of antioxidants for gene modulation
11/21/2012CN102784395A Application of MAPK-ERK1/2 signal channel inhibitor to preparation of double-minute medicine for removing or inhibiting tumor cells
11/21/2012CN102784394A Use of PDE III Inhibitors for the Treatment of Asymptomatic (Occult) Heart Failure
11/21/2012CN102784393A Use of Toll-like receptor 5 (TLR5) agonist stFla in anti-pulmonary fibrosis
11/21/2012CN102784113A Granules comprising a nsaid and a sugar alcohol made by melt extrusion
11/21/2012CN102784111A Sustained-release preparation of dopamine receptor agonist drugs
11/21/2012CN101378771B Nutritional system and methods for increasing longevity
11/21/2012CN101365423B Sustained release small molecule drug formulation
11/20/2012US8314104 Method of treating diabetes
11/20/2012US8314084 Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
11/20/2012US8313927 Ucp4
11/20/2012US8313769 Rapidly disintegrating dosage form for releasing active ingredients in the oral cavity or in body cavities
11/20/2012US8313767 Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle
11/20/2012US8313751 Compositions and methods for the prophylaxis or treatment of viral diseases
11/20/2012US8313739 Use of truncated cysteine IL28 and IL29 Mutants to treat cancers and autoimmune disorders
11/20/2012US8313732 Formoterol superfine formulation
11/20/2012CA2633171C Antibodies against tumor-associated antigenic target (tat) polypeptides
11/20/2012CA2529878C Pyrazole derivative, drug composition containing the same and production intermediate therefor
11/20/2012CA2426679C Preventive or therapeutic agent for psoriasis comprising il-6 antagonist as active ingredient
11/20/2012CA2318095C Methods of treating tardive dyskinesia and other movement disorders
11/15/2012WO2012154480A1 c-KIT ANTIBODIES AND USES THEREOF
11/15/2012WO2012154340A1 Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
11/15/2012WO2012154122A2 A topical formulation for treatment of hyperkeratotic skin
11/15/2012WO2012153616A1 Lipid membrane structure capable of imigrating to target cell and method for producing same, and method for screening for substance exhibiting effect thereof in target cell
11/15/2012WO2012153493A1 Photodynamic therapy or diagnostic agent, using infrared-spectrum light
11/15/2012WO2012152885A1 Combination of a statin and a taxane for the treatment of gastric cancer
11/15/2012WO2012107765A3 Particle formulation
11/15/2012US20120289601 Gastric Retained Gabapentin Dosage Form
11/15/2012US20120289542 Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
11/15/2012US20120289515 Combination therapy for cognitive distortions, resisting relapse of unipolar non-psychotic depression
11/15/2012US20120289452 Compositions and methods for treating and preventing necrosis
11/15/2012US20120288567 Opioid Agonist Formulations with Releasable And Sequestered Antagonist
11/15/2012US20120288565 Tamper-resistant oral opioid agonist formulations
11/15/2012CA2835874A1 A topical formulation for treatment of hyperkeratotic skin
11/15/2012CA2835200A1 C-kit antibodies and uses thereof
11/15/2012CA2831351A1 Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
11/14/2012EP2522365A1 Compositions comprising azelastine and methods of use thereof
11/14/2012EP2522364A1 Method of treating hemolytic disease
11/14/2012EP2522363A1 Method of treating hemolytic disease
11/14/2012EP2522362A1 Method of treating hemolytic disease
11/14/2012EP2522361A1 Method of treating hemolytic disease
11/14/2012EP2522356A2 Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer
11/14/2012EP2522351A1 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
11/14/2012EP2522342A1 A topical formulation for treatment of hyperkeratotic skin
11/14/2012EP2521913A1 Methods and compositions for treating cancer
11/14/2012EP2521569A1 Combined treatment utilizing vb-201
11/14/2012EP2521546A2 Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
11/14/2012EP2521543A1 A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
11/14/2012CN1338947B Novel mucosal delivery system
11/14/2012CN102782129A Pharmaceutical composition
11/14/2012CN102781473A Pharmaceutical composition for external use
11/14/2012CN102781434A Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
11/14/2012CN102781430A Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
11/14/2012CN102781424A Use of levodopa, carbidopa and entacapone for treating parkinson's disease
11/14/2012CN102778566A Application of DLK1 in diagnosis and prognosis of liver cancer
11/14/2012CN102775396A Modulators of ATP-binding cassette transporters
11/14/2012CN102772801A Wound spray for treating bruises and preparation method of wound spray
11/14/2012CN102772800A Application of medicament of target adenosine receptor A2BAR in preparing medicament for preventing or treating autoimmune diseases
11/14/2012CN102772424A Application of neohesperidin in preparing of diabetes preventive treatment medicines
11/14/2012CN102772413A Low dose entecavir formulation and use
11/14/2012CN102772411A Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases
11/14/2012CN102772380A Solid pharmaceutical dosage form
11/14/2012CN102772357A Implantable polymeric device for sustained release of dopamine agonist
11/14/2012CN101756957B Pharmaceutical composition containing artemisinin, artemisinin derivatives and histon deacetylase (HDAC) inhibitor and application thereof
11/14/2012CN101732728B Anti-inflammatory drug (polysaccharide conjugate) as well as preparation and application of drug composition thereof
11/14/2012CN101496827B Application of pumpkin protein in preparing medicament for treating chronic myeloid leukemia
11/14/2012CN101472571B Treating obesity with muscarinic receptor m1 antagonists
11/14/2012CN101232822B Composition for reducing the risc of ethanol metabolism and alcohol induced neuropathy
11/14/2012CN101048064B Antiseptic compositions and methods of use
11/13/2012US8309788 Protease inhibitors in absorbent articles
11/13/2012US8309574 Nuclear transfer promoter for Rac protein and method of screening the same
11/13/2012US8309570 E.g., dextromethorphan hydrobromide, amantadine, memantine, remacemide or riluzole; treating pain resulting from injury, trauma, lesion or other disorders in the spinal cord or brain
11/13/2012US8309560 Methods and compositions for ameliorating the undesirable effects of chemotherapy
11/13/2012US8309535 Compositions and methods to treat recurrent medical conditions
11/13/2012US8309527 For use as antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics
11/13/2012US8309125 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
11/13/2012US8309087 Treatment with anti-ErbB2 antibodies
1 ... 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 ... 1151